The CEO of BioNTech Ugur Sahin was inoculated in early 2021 with the COVID-19 vaccine his team developed with Pfizer, a ...

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

Germany's campaign will use Pfizer/BioNTech and Moderna vaccines, regardless of which type was administered for the first and second doses. The news comes amid reports that prices charged to ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Buy rating to BioNTech SE (BNTX – Research Report). The ...

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...

Pharma majors like BioNTech in Germany and Pfizer in the United States have made profits in billions of dollars in selling ...

The Germany-based company has agreed to pay $791.5 million to the U.S. agency, whereas it would pay $467 million to UPenn to dismiss the lawsuit. Moreover, BioNTech's partner Pfizer (PFE ...

Genomics is becoming the future of medicine as technological advancements continue to unlock our DNA’s vast potential. Given ...

More about BioNTech SE BioNTech SE is a biotechnology company based in Mainz, Germany, primarily known for its development of mRNA-based vaccines and immunotherapies. The company is a significant ...

BioNTech SE operates as immunotherapy company ... 2008 and is headquartered in Mainz, Germany.

Truist sets BioNTech's price target at $172, highlighting BNT327's revenue potential of $6B+ across multiple cancer indications. BioNTech's BNT327 could lead U.S. and European approvals for key ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...